Home » Topics » Regulatory » EMA

EMA
RSS

Obeticholic acid receives E.U. orphan drug status for primary biliary cirrhosis

Aug. 10, 2010

Celgene's pomalidomide receives E.U. orphan drug status for myelofibrosis

Aug. 10, 2010

EMA's CHMP issues positive opinion on Relistor in prefilled syringes

Aug. 6, 2010

COMP recommends orphan drug status for XOMA-052 in Behcet's disease

July 30, 2010

Bionovo moves Menerba to phase III testing in Europe

July 30, 2010

CHMP issues positive opinion on Arixtra use for superficial vein thrombosis

July 27, 2010

CHMP issues positive opinion on Twynsta for hypertension

July 26, 2010

EMA provides update on benefit-to-risk review of Avandia, Avandamet and Avaglim

July 26, 2010

EMA recommends restricting modafinil use

July 26, 2010

CHMP concludes topical ketoprofen has positive benefit-to-risk balance

July 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...